Portfolio Optimization
Multi-objective optimizer for trial selection across your network
REVENUE
35%
weight
ENROLLMENT
25%
weight
RISK MINIMIZATION
25%
weight
TA BALANCE
15%
weight
Optimization Configuration
OPTIMIZATION OBJECTIVES
35%
25%
25%
15%
Total Weight: 100%
CONSTRAINTS
$
The optimizer will only consider trial opportunities with a feasibility score of 60 or higher.
AVAILABLE TRIALS
8
opportunities
TOTAL POTENTIAL REVENUE
$8.3M
across all trials
TOTAL ENROLLMENT
330
patients
HIGH-SCORING TRIALS
3
feasibility ≥ 80
Available Trial Opportunities
Configure objectives and constraints above, then click Optimize to select the best portfolio
ONCO-NOVA-401
Oncology • PHASE III
88
Revenue:$1350K
Enrollment:45
CARDIO-APEX-202
Cardiology • PHASE II
82
Revenue:$1200K
Enrollment:60
NEURO-PATH-301
Neurology • PHASE III
76
Revenue:$1225K
Enrollment:35
ENDO-METAB-305
Endocrinology • PHASE III
91
Revenue:$1600K
Enrollment:80
ONCO-BREAST-201
Oncology • PHASE II
72
Revenue:$625K
Enrollment:25
PULMO-COPD-205
Pulmonology • PHASE II
79
Revenue:$800K
Enrollment:40
CARDIO-HEART-101
Cardiology • PHASE I
64
Revenue:$600K
Enrollment:15
NEURO-MS-204
Neurology • PHASE II
69
Revenue:$900K
Enrollment:30